Services by Pharmacy PGD Xifaxanta PGDXifaxanta can be supplied by Pharmacists without a doctor’s prescription through a patient group direction (PGD) from the ‘Pharmacy PGD’ website, www.pharmacypgd.co.uk.
Training is all online. Once Pharmacists are trained, the forms and leaflets needed to start using the PGD can be printed from the website. Pharmacists can train and start using PGDs in the same day.
Pharmacies set their own fee for the service.
Approval from PCTs or Trusts is not required.
About Pharmacy PGDPharmacy PGD is a provider of patient group directions (PGDs). PGDs are written directions which allow health professionals, including Pharmacist, to supply prescription medications and other services to patients under specified circumstances.
‘Pharmacy PGD’ provides a range of useful PGDs, including one
for travellers’ diarrhoea, which allows for the supply of Xifaxanta. There are other travel related PGDs and PGDs for a range of popular services. See list below.
Each PGD consists of an online training pack which provides background medical information and an explanation about how to use the PGD. The assessment forms complete by customers and a quick guide for Pharmacists to help them apply PGDs can be downloaded from the website. The process is streamlined, and quick and efficient.
• Register and train FREE at www.pharmacypgd.co.uk
• Erectile Dysfunction (Viagra, Cialis, Levitra)
• PGDs cost from £45–£65 per year to use
• Anti-Malarials (Malarone, Doxycyline)
• Consultations are undertaken in-store
• Colour posters are available to order to advertise your
• Emergency Contraception (Levonelle 1500)
• Vaccine training courses throughout the UK
• Salbutamol Inhalers (asthma inhaler)
(separate payment for practical vaccination training)
• Oral Contraceptive Pills (all brands)
• Private PGDs – no PCT/Trust approval needed
• Forms, leaflets and posters available
• Counts towards CPD (continuing professional
Provided to you on behalf of Red Box by Norgine Pharmaceuticals Limited
XIFAXANTA Prescribing Information
REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS
(SmPC) BEFORE PRESCRIBING Presentation:
Film-coated tablet containing rifaximin 200 mg. Uses:
Xifaxanta is indicated for the treatment of travellers’ diarrhoea that is not associated
with fever, bloody diarrhoea, eight or more unformed stools in the previous 24 h, occult blood
or leucocytes in the stool. Dosage and administration:
Adults over 18 years of age: 200
mg every 8 hours for three days (total 9 doses). Rifaximin must not be used for more than
3 days even if symptoms continue and a second course of treatment must not be taken. Not
recommended in children under 18 years of age. Contraindications:
Hypersensitivity to the
active substance, to any rifamycin (e.g. rifampicin or rifabutin) or to any of the excipients. Warnings and precautions for use:
Not recommended for the treatment of travellers’
diarrhoea caused by invasive enteric pathogens. If symptoms worsen, treatment with rifaximin
should be interrupted. If symptoms have not resolved after 3 days of treatment, or recur
shortly afterwards, a second course is not recommended. The potential association of rifaximin
treatment with Clostridium difficile associated diarrhoea and pseudomembranous colitis
cannot be ruled out. Interactions:
Due to the negligible gastrointestinal absorption of orally
administered rifaximin (less than 1%), the systemic drug interaction potential is low. Rifaximin
should not be administered concomitantly with other rifamycins and the tablets should not
be administered for at least two hours after the administration of charcoal. Pregnancy and
Rifaximin is not recommended during pregnancy and in women of childbearing
potential not using contraception. The benefits of rifaximin treatment should be assessed against
the need to continue breastfeeding. Undesirable effects:
Common effects reported in clinical
trials are dizziness, headache, abdominal pain, constipation, defecation urgency, diarrhoea,
flatulence, bloating, distension, nausea, vomiting, rectal tenesmus and pyrexia. Other effects
that have been reported are candidiasis, herpes simplex infections, clostridial infections,
palpitations, increased blood pressure, liver function test abnormalities, blood disorders (e.g
thrombocytopenia) and anaphylactic reactions, (eg, angioedemas, hypersensitivity and skin
reactions). Licensing and legal category:
Legal category: POM. Cost: Basic NHS price £15.15
(9 tablets), MA number: PL 20011/0021. Date of preparation/revision:
Adverse events should be reported. Reporting forms and information can be found
at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Medical
Information at Norgine Pharmaceuticals Ltd on 01895 826606.
For further information contact:
Norgine Pharmaceuticals LimitedNorgine HouseMoorhall RoadHarefieldMiddlesexUB9 6NS
Evaluation of Asymptomatic Microscopic Hematuria in Adults - Septembe. http://www.aafp.org/afp/AFPprinter/990915ap/1143.html?print=yes Evaluation of Asymptomatic Microscopic Hematuria in Adults University of Kansas Medical Center, Kansas City, Kansas hematuria, written by theValley Urology Center, Renton, WashingtonIn patients without significant urologic symptoms, microscopic hematu
1. The 2-oxoacid dehydrogenase complex of haloferax volcanil ; Dina Musaed Al-Mailem; 2006. QR 97 .S3 M34 2006 SC 2. Ab Initio study of the absorption of organic molecules on metal oxide surfaces ; Mariam Riad Abdallah; Kuwait University: Kuwait, 2007. QD 505 .A23 2007 SC 3. Alkalinity and salinity loving (tolerant) oil-utilizing microorganisms from Kuwait coasts ; Rasha Ham